Alacris Theranostics enters agreement with GSK to use ModCellTM System for early stage cancer research

Berlin, 14th November 2012 – Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris’ proprietary ModCell™ System, developed at the Max Planck Institute for Molecular Genetics and licensed exclusively to Alacris, for drug stratification using data from early stage cancer drug discovery at GSK.

GSK will provide to Alacris pre-clinical biology data from a drug discovery project in oncology. Alacris will exploit its proprietary Systems Biology model to determine the in silico effect of the inhibitor in its “virtual clinical trial” system. Alacris will then suggest which cancer cell lines as well as which cancers are more likely to respond to the inhibitor. This will be based on whole genome and transcriptome data that is integrated in the Alacris’ cancer model ModCellTM.

Read the entire Press release